583 results on '"Verbeek, Marcel M."'
Search Results
2. Temporal Ordering of Biomarkers in Dutch-Type Hereditary Cerebral Amyloid Angiopathy
3. Decreased ratios of matrix metalloproteinases to tissue-type inhibitors in cerebrospinal fluid in sporadic and hereditary cerebral amyloid angiopathy
4. An emerging biomarker for dopaminergic cell loss
5. An attenuated, adult case of AADC deficiency demonstrated by protein characterization
6. Proximity extension assay in cerebrospinal fluid identifies neurofilament light chain as biomarker of neurodegeneration in sporadic cerebral amyloid angiopathy
7. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy
8. Divergent Associations of Slow‐Wave Sleep versus Rapid Eye Movement Sleep with Plasma Amyloid‐Beta
9. Factors associated with mortality in early stages of parkinsonism
10. Mechanisms of peripheral levodopa resistance in Parkinson’s disease
11. Profiling amyloid‐β peptides as biomarkers for cerebral amyloid angiopathy.
12. Altered brain expression and cerebrospinal fluid levels of TIMP4 in cerebral amyloid angiopathy.
13. Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia
14. The novel P330L pathogenic variant of aromatic amino acid decarboxylase maps on the catalytic flexible loop underlying its crucial role
15. Translational validation of shotgun proteomics findings in cerebrospinal fluid of sporadic cerebral amyloid angiopathy patients
16. Cerebrospinal fluid shotgun proteomics identifies distinct proteomic patterns in cerebral amyloid angiopathy rodent models and human patients
17. Shotgun proteomics for the discovery of protein biomarkers for cerebral amyloid angiopathy
18. Full complement activation is associated with capillary cerebral amyloid angiopathy in Alzheimer’s disease.
19. Profiling amyloid‐β peptides as diagnostic biomarkers for cerebral amyloid angiopathy
20. Identification of CSF biomarkers for cerebral amyloid angiopathy using a targeted proteomics approach
21. Tissue inhibitor of matrix metalloproteinases 4: a novel marker associated with CAA
22. The relation of a cerebrospinal fluid profile associated with Alzheimer's disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy.
23. Succinic semialdehyde dehydrogenase deficiency in mice and in humans: An untargeted metabolomics perspective.
24. Neuropsychiatric symptoms with focus on apathy and irritability in sporadic and hereditary cerebral amyloid angiopathy.
25. Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase
26. Correction to: Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy
27. Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy
28. Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach
29. MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy
30. Cerebrospinal fluid myelin basic protein is elevated in multiple system atrophy
31. Linking APOE-ε4, blood-brain barrier dysfunction, and inflammation to Alzheimer's pathology
32. Reinforcement learning in Parkinson’s disease is not associated with inflammatory tone
33. Reduced Influence of apoE on Aβ43 Aggregation and Reduced Vascular Aβ43 Toxicity as Compared with Aβ40 and Aβ42
34. Valuing biomarker diagnostics for dementia care: enhancing the reflection of patients, their care-givers and members of the wider public
35. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study
36. Autoimmune Encephalitis Resembling Dementia Syndromes
37. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review
38. Activation of TNF Receptor 2 Improves Synaptic Plasticity and Enhances Amyloid-β Clearance in an Alzheimer’s Disease Mouse Model with Humanized TNF Receptor 2
39. Succinic semialdehyde dehydrogenase deficiency in mice and in humans: An untargeted metabolomics perspective
40. Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy
41. Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease
42. Cerebral tryptophan metabolism and outcome of tuberculous meningitis: an observational cohort study
43. Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson’s disease
44. Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls
45. Reply to: Letter for: Decreased cerebrospinal fluid A β 38, 40, 42, and 43 levels in sporadic and hereditary cerebral amyloid angiopathy
46. Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer’s Disease
47. Reader response: Blood NfL: A biomarker for disease severity and progression in Parkinson disease
48. Disturbed balance in the expression of MMP9 and TIMP3 in cerebral amyloid angiopathy-related intracerebral haemorrhage
49. Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms
50. Aβ43 in human Alzheimer’s disease: effects of active Aβ42 immunization
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.